| Industry | 制造业 | ||||||||||||||||||||||||
| Company Introduction | 金凯生科是一家面向全球生命科技领域客户的小分子CDMO服务商，为全球原研药厂的新药研发项目提供小分子药物中间体以及少量原料药的定制研发生产服务，协助其解决创新药研发过程中化合物合成的工艺开发、工艺优化、工艺放大和规模化生产等难题，有效提高原研药厂新药研发效率，降低其新药研发生产成本。公司的核心产品应用于肿瘤、心脑血管、糖尿病、肌萎缩侧索硬化（渐冻症）、阿尔茨海默症、艾滋病、新型冠状病毒等多个疾病治疗领域，与包括拜耳、强生、诺华、赛诺菲、吉利德、阿斯利康、辉瑞、默克、GSK、礼来、武田、勃林格殷格翰等国际大型医药及生物制药集团，ConcertPharmaceutical、Biogen、Principia、SeattleGenetics等特色治疗领域的创新药企业建立了业务合作关系。此外，发行人也为巴斯夫等跨国化工集团提供从产品试验到商业化应用所需农药中间体的配套研发和生产服务。 发行人为世界大型跨国医药及生物制药集团、创新药公司、化工集团提供的CDMO服务就是将化合物工艺路线的研发与生产深度结合的过程。经过多年技术创新发展，发行人能够自主研发众多小分子化合物的工艺路线，解决生产过程中的技术瓶颈，并利用公司全面的反应能力保证研发的技术路线得以实施。公司掌握包括氟化反应、氯化反应、光气化反应、硼酸化反应、低温反应、手性合成等多种技术能力，其中在氟化领域，公司的氟化氢氟化、氟化钾氟化、四氟化硫氟化、特殊氟化剂氟化（如氟化氢吡啶、氟化氢三乙胺等）以及电解氟化等特色工艺技术，能够为客户在含氟药物领域提供高效率、高质量、低成本、安全环保的中间体或原料药定制研发、生产服务。 | ||||||||||||||||||||||||
| Main Business | 面向全球生命科技领域客户的小分子CDMO服务商，为全球原研药厂的新药研发项目提供小分子药物中间体以及少量原料药的定制研发生产服务。 | ||||||||||||||||||||||||
| Legal Representative | 王富民 | ||||||||||||||||||||||||
| Top Executives |
|
||||||||||||||||||||||||
| Top 5 Shareholder |
|
||||||||||||||||||||||||
| Company Secretary | 王琦 | ||||||||||||||||||||||||
| Solicitors | 北京市中伦律师事务所 | ||||||||||||||||||||||||
| Auditors | 安永华明会计师事务所（特殊普通合伙） | ||||||||||||||||||||||||
| Tel No | 0418-6327768 | ||||||||||||||||||||||||
| Fax No | 0418-6327767 | ||||||||||||||||||||||||
| Website | www.kingchemchina.com | ||||||||||||||||||||||||
| bod.office@kingchemchina.com | |||||||||||||||||||||||||
| Company Address |
|
||||||||||||||||||||||||
| Listing Date | 03/08/2023 | ||||||||||||||||||||||||
| Shares Capital |
|
||||||||||||||||||||||||
| EPS(RMB)* | ¥ 2.420 | ||||||||||||||||||||||||
| DPS(RMB)* | ¥ 0.800 | ||||||||||||||||||||||||
| NBV Per Share(RMB)* | ¥ 25.234 | ||||||||||||||||||||||||
| Market Capitalization(RMB) | 1.418B |
 |
Only Chinese content is avaliable |
|
N
/
N
: Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SH-HK Ex-Northbound trade (sell only)
|
|
|
N
/
N
: Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
: Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
|
|
| * | Unadjusted Data |
| Information provided by: etnet | ||
| Terms and Conditions | ||
| Risk Disclosure: |
| The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone. |
| Disclaimer: |
| This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information. |